AVRA Medical Robotics, Inc. (AVMR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AVRA Medical Robotics, Inc. (AVMR) trades at $9.17 with AI Score 61/100 (Grade B+). AVRA Medical Robotics, Inc. is focused on developing and manufacturing medical surgical devices, particularly robotic devices for minimally invasive facial corrections. Market cap: $494.15M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for AVMR: AVMR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AVMR against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
AVMR: 2/4 perspectives are bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →AVRA Medical Robotics, Inc. (AVMR) Healthcare & Pipeline Overview
AVRA Medical Robotics, Inc. is a medical device company specializing in the development of surgical robotic technology for minimally invasive facial corrections. With a research agreement with the University of Central Florida, AVRA aims to innovate within the medical devices sector, despite its current OTC market status and limited operational scale.
What Is the Investment Thesis for AVMR?
AVRA Medical Robotics, Inc. presents a high-risk, high-reward investment opportunity due to its focus on developing innovative surgical robotic technology. The company's research agreement with the University of Central Florida provides a foundation for technological advancement in minimally invasive facial corrections. However, the company's OTC market status, negative profit margin of -28.6%, and limited operational scale (2 employees) introduce significant uncertainties. Key value drivers include successful prototype development, regulatory approvals, and potential partnerships with larger medical device companies. Upcoming catalysts include milestones in the research agreement with the University of Central Florida and potential funding announcements. The company's high beta of -52.75 suggests extreme volatility. Investors should carefully consider the risks associated with investing in a small, development-stage company operating in the highly competitive medical devices industry.
Based on FMP financials and quantitative analysis
AVMR Key Highlights
- Market Cap of $494.15M reflects investor speculation in the company's potential, despite its early stage of development.
- P/E Ratio of -74.42 indicates the company is currently unprofitable, typical for development-stage companies in the medical device sector.
- Gross Margin of 45.3% demonstrates potential profitability of the company's products, assuming successful commercialization.
- The company's research agreement with the University of Central Florida provides a foundation for technological advancement in minimally invasive facial corrections.
- OTC market status introduces risks related to liquidity and regulatory oversight.
Who Are AVMR's Competitors?
AVMR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CCHWF Columbia Care Inc. | $0.94 | -21.71% | $521.35M | 41 |
| CKDXF Opthea Limited | $0.01 | +0.00% | $13.68M | 53 |
| DFHL Dong Fang Hui Le Inc. | $4.00 | -11.11% | $400.40M | 44 |
| HYBT Heyu Biological Technology Corporation | $0.35 | -41.67% | $361.36M | 42 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AVMR's Key Strengths?
- Innovative surgical robotic technology.
- Research partnership with a reputable university.
- Focus on a specific niche market (facial corrections).
- Potential for minimally invasive surgical solutions.
What Are AVMR's Weaknesses?
- Limited operational scale (2 employees).
- OTC market listing.
- Negative profit margin.
- Dependence on research progress.
What Could Drive AVMR Stock Higher?
- Milestones in the research agreement with the University of Central Florida regarding the surgical robotics prototype.
- Potential announcements regarding funding or partnerships with medical device companies.
- Progress towards regulatory approvals for the company's surgical robotic device.
- Development and refinement of the surgical robotics technology.
- Exploration of additional applications for the company's technology beyond facial corrections.
What Are the Key Risks for AVMR?
- Negative return on equity (-23.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to secure additional funding for research and development.
- Delays or setbacks in the regulatory approval process.
- Competition from established medical device companies with greater resources.
- Limited operational scale and financial resources.
- Risks associated with investing in OTC stocks, including limited liquidity and regulatory oversight.
What Are the Growth Opportunities for AVMR?
- Advancement of Surgical Robotics Prototype: The ongoing research agreement with the University of Central Florida represents a significant growth opportunity for AVRA. Successful development of a functional prototype for minimally invasive facial corrections could attract further investment and partnerships. The market for surgical robotics is projected to reach $14.7 billion by 2027, presenting a substantial opportunity for AVRA if its technology proves viable. Timeline: Ongoing, with potential milestones expected in the next 12-24 months.
- Strategic Partnerships and Collaborations: Forming strategic alliances with established medical device companies or healthcare providers could accelerate AVRA's product development and market access. Collaborations could provide access to funding, expertise, and distribution channels. The medical device industry is characterized by partnerships between smaller innovators and larger players, creating opportunities for AVRA to leverage its technology. Timeline: Ongoing, with potential partnerships emerging within the next 2-3 years.
- Expansion of Product Portfolio: While currently focused on facial corrections, AVRA could expand its product portfolio to address other areas of minimally invasive surgery. This diversification would broaden the company's market reach and reduce its reliance on a single product line. The broader market for minimally invasive surgical devices is estimated at $21.47 billion in 2024 and is expected to grow. Timeline: Long-term, with potential expansion beyond facial corrections in 3-5 years.
- Securing Regulatory Approvals: Obtaining regulatory approvals from bodies such as the FDA is crucial for commercializing AVRA's surgical robotic device. Successful navigation of the regulatory process would validate the safety and efficacy of the technology, paving the way for market entry. The regulatory approval process can be lengthy and costly, but it is a necessary step for any medical device company. Timeline: Ongoing, with potential FDA approval within 2-4 years, assuming successful clinical trials.
- Attracting Venture Capital Funding: Securing additional venture capital funding is essential for supporting AVRA's research and development efforts. Increased funding would enable the company to accelerate its prototype development, conduct clinical trials, and expand its team. The venture capital market for medical devices is competitive, but innovative technologies with strong market potential can attract significant investment. Timeline: Ongoing, with potential funding rounds occurring in the next 12-18 months.
What Opportunities Does AVMR Have?
- Expanding product portfolio to other surgical areas.
- Securing additional funding and partnerships.
- Gaining regulatory approvals for commercialization.
- Capitalizing on the growing market for surgical robotics.
What Threats Does AVMR Face?
- Competition from established medical device companies.
- Regulatory hurdles and approval delays.
- Technological obsolescence.
- Limited financial resources.
What Are AVMR's Competitive Advantages?
- Proprietary robotic surgical technology.
- Research agreement with the University of Central Florida.
- Focus on a niche market (facial corrections).
What Does AVMR Do?
AVRA Medical Robotics, Inc., founded in 2015 and based in Orlando, Florida, is a medical device company focused on the development and manufacturing of surgical robotic devices. Originally named AVRA Surgical Microsystems, Inc., the company rebranded in November 2015 to reflect its strategic shift towards robotics. AVRA is currently engaged in a research agreement with the University of Central Florida to develop a prototype surgical robotic device designed to support minimally invasive surgical facial corrections. This collaboration underscores AVRA's commitment to innovation in the medical field, specifically targeting the niche market of facial reconstructive surgery. AVRA's business model centers around the research, development, and eventual commercialization of its robotic surgical technology. While still in the early stages of development, the company aims to create a product that enhances precision and reduces invasiveness in facial surgical procedures. The company's small size, with only 2 employees, reflects its current stage as a research-focused entity. The company's headquarters are located in Orlando, Florida. AVRA Medical Robotics operates within the broader medical devices industry, which is characterized by rapid technological advancements and stringent regulatory requirements. The company's success hinges on its ability to successfully navigate the regulatory landscape, secure additional funding, and demonstrate the clinical efficacy and safety of its robotic surgical device. As a smaller player in a competitive market, AVRA faces challenges related to resource constraints and market access. AVRA's future growth depends on continued innovation and strategic partnerships.
What Products and Services Does AVMR Offer?
- Develops medical surgical devices.
- Manufactures medical surgical devices.
- Focuses on robotic technology for surgical applications.
- Collaborates with the University of Central Florida on research.
- Aims to create minimally invasive surgical solutions.
- Targets facial corrections as a primary application.
How Does AVMR Make Money?
- Research and development of surgical robotic devices.
- Seeking partnerships for technology commercialization.
- Potential revenue generation through device sales and licensing agreements.
What Industry Does AVMR Operate In?
AVRA Medical Robotics, Inc. operates within the medical devices industry, a sector characterized by continuous innovation and technological advancements. The global medical devices market is projected to reach trillions of dollars by 2026, driven by an aging population, increasing prevalence of chronic diseases, and demand for minimally invasive surgical procedures. AVRA's focus on surgical robotics aligns with the trend towards robotic-assisted surgery, which offers enhanced precision, reduced recovery times, and improved patient outcomes. Competitors include established medical device companies and specialized robotics firms, such as CCHWF (Columbia Care Inc.), CKDXF (Check-Cap Ltd.), CLAZF (Calazans AG), DFHL (DFH Co Ltd), and HYBT (Hybot Medical Technology Co Ltd). AVRA's success depends on its ability to differentiate its technology and secure regulatory approvals.
Who Are AVMR's Key Customers?
- Hospitals and surgical centers.
- Facial surgeons and reconstructive specialists.
- Patients seeking minimally invasive surgical options.
Net buyingInsider Activity
The most recent 9 insider filings for AVRA Medical Robotics, Inc. break down as 5 sales and 4 purchases. On net that is roughly 5.0M shares acquired (about $21.1M) — insiders putting money in tends to read as conviction.
F-Score 2/9Financial Health
AVRA Medical Robotics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 8.18 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE -23%Key Financial Metrics
Return on equity for AVRA Medical Robotics, Inc. stands at -23.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.54 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.5%, the inverse of the P/E and a quick read on earnings relative to price.
AVRA Medical Robotics, Inc. (AVMR) Valuation Context
Valued at $494.15M, AVMR is classified as a small-cap stock. Relative to its peer group, AVMR's quantitative score of 61/100 is above the peer average of 51/100.
AVMR Revenue & Earnings Trend
In Q1 2026, AVMR generated $11.1M in top-line revenue, marking a sequential decrease of 23.6%. The company recorded a net loss of $3.6M, with diluted EPS of $-0.02. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, AVMR averaged $-0.01 in diluted EPS.
Company Profile
AVRA Medical Robotics, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Orlando, US. The company is led by CEO Barry F. Cohen.
AVMR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in AVRA's future, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative technology AVRA brings to the medical robotics field.
- AVRA's partnerships with healthcare institutions are gaining traction, enhancing its visibility and credibility in a competitive market.
- Recent advancements in their product line have sparked excitement, positioning AVRA as a potential leader in a growing industry.
Bear Case
- Concerns over regulatory hurdles in the medical sector have surfaced, causing skepticism about AVRA's ability to navigate compliance effectively.
- Some community members express doubts about AVRA's scalability, questioning whether the company can meet increasing demand without compromising quality.
- Recent competition from established players in the medical robotics space has raised alarms, with some investors worried about AVRA's market share.
- Overall market volatility has led to cautious sentiment, with investors wary of smaller companies like AVRA amidst broader economic uncertainties.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $11M | -$4M | -$0.02 |
| Q4 2025 | $15M | -$2M | -$0.01 |
| Q3 2025 | $13M | -$4M | -$0.02 |
| Q2 2025 | $10M | -$256,691 | -$0.0013 |
Based on FMP financials and quantitative analysis
AVMR Latest News
No recent news available for AVMR.
AVMR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AVMR.
Price Targets
Wall Street price target analysis for AVMR.
AVMR MoonshotScore
What does this score mean?
The MoonshotScore rates AVMR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Barry F. Cohen
CEO
Barry F. Cohen serves as the CEO of AVRA Medical Robotics, Inc. His background and experience prior to joining AVRA are not provided in the available data. As the head of a small company with only 2 employees, Cohen is likely involved in all aspects of the business, from strategic planning to day-to-day operations. His leadership is crucial for guiding the company through its early stages of development and commercialization.
Track Record: Given the limited information available, it is difficult to assess Barry F. Cohen's track record at AVRA Medical Robotics. The company is still in its early stages, and its success will depend on Cohen's ability to secure funding, advance its technology, and navigate the regulatory landscape. The company's progress in its research agreement with the University of Central Florida will be a key indicator of his leadership effectiveness.
AVMR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that AVRA Medical Robotics, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited operating history, minimal assets, and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significant risks due to the potential for fraud, lack of transparency, and limited liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to OTC Other listing.
- Lack of regulatory oversight and financial disclosure.
- Potential for price manipulation and fraud.
- High volatility and speculative trading.
- Uncertainty regarding the company's long-term viability.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's technology and intellectual property.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Confirm the company's good standing with the Secretary of State in its state of incorporation.
- Research agreement with the University of Central Florida.
- Focus on developing innovative surgical robotic technology.
- Company has been in operation since 2015.
- Gross Margin of 45.3% demonstrates potential profitability of the company's products, assuming successful commercialization.
- The company's headquarters are located in Orlando, Florida.
AVMR Healthcare Stock FAQ
What does AVRA Medical Robotics, Inc. do?
AVRA Medical Robotics, Inc. is a medical device company focused on developing and manufacturing surgical robotic devices. The company is currently engaged in a research agreement with the University of Central Florida to develop a prototype surgical robotic device designed to support minimally invasive surgical facial corrections. AVRA aims to innovate within the medical devices sector, specifically targeting the niche market of facial reconstructive surgery. The company is still in the early stages of development and commercialization.
What are the main risks for AVMR?
The main risks for AVRA Medical Robotics, Inc. include its OTC market listing, which introduces risks related to liquidity and regulatory oversight. The company's limited operational scale and negative profit margin also pose challenges. Additionally, there are risks associated with the development and commercialization of its surgical robotic device, including regulatory hurdles, competition from established medical device companies, and the need for additional funding. Investors should carefully consider these risks before investing in AVMR.
What are the key factors to evaluate for AVMR?
AVRA Medical Robotics, Inc. (AVMR) holds an AI score of 61/100 (moderate). Not financial advice.
How frequently does AVMR data refresh on this page?
AVMR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AVMR's recent stock price performance?
AVRA Medical Robotics, Inc. (AVMR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative surgical robotic technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AVMR overvalued or undervalued right now?
Valuing AVRA Medical Robotics, Inc. (AVMR) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AVMR?
Before investing in AVRA Medical Robotics, Inc. (AVMR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding AVMR to a portfolio?
Key strength of AVRA Medical Robotics, Inc. (AVMR): Innovative surgical robotic technology. Its MoonshotScore of 61/100 reflects solid quantitative fundamentals. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC market status introduces additional risks and uncertainties.
- AI analysis is pending.